(Total Views: 567)
Posted On: 02/01/2022 2:24:20 PM
Post# of 153908
Re: onestepahead #117076
$30B for a drug to treat an untapped market (NASH) with a super duper safety profile (better than placebo) sounds like a good deal for BP.
Get a drug to treat mTNBC and other cancers (potential monotherapy) for a few tens of billions more with a super duper safety profile (better than placebo) sounds like a good deal for BP.
But BP likely subtracts the revenue they lose from inferior drugs.
It'd be best if TSLA just opened a biotech arm and spent 10% of their market cap to acquire LL. Then they can fuck up BP like they did with legacy auto.
Get a drug to treat mTNBC and other cancers (potential monotherapy) for a few tens of billions more with a super duper safety profile (better than placebo) sounds like a good deal for BP.
But BP likely subtracts the revenue they lose from inferior drugs.
It'd be best if TSLA just opened a biotech arm and spent 10% of their market cap to acquire LL. Then they can fuck up BP like they did with legacy auto.
(3)
(0)
